Myosin light chain kinase is a potential target for hypopharyngeal cancer treatment.

In conclusion, MLCK is a novel prognostic marker and therapeutic target for hypopharyngeal cancer. By targeting MLCK, ATPR exhibits its potential application in the treatment of this type of cancer.
PMID: 32920510 [PubMed - as supplied by publisher]

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 9, 2020 Category: Drugs & Pharmacology Authors: Cao F, Zhu L, Zhang J, Pongkorpsakol P, Kuo WT, Turner JR, Zhou Q, Wang Y, Chen F, Liu Y, Zuo L Tags: Biomed Pharmacother Source Type: research